echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The production site inspection of levetiracetam, an antiepileptic drug of xinlitai, has been completed

    The production site inspection of levetiracetam, an antiepileptic drug of xinlitai, has been completed

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    At the performance presentation meeting, Yang Jianfeng, Secretary of the board of directors of xinlitai, said that the drug regulatory department had come to the company this month to inspect the production site of the antiepileptic drug levetiracetam "The domestic antiepileptic drug market has a significant growth momentum, and the company believes that the product has a good market potential." According to the website of the State Food and drug administration, the on-site inspection of levetiracetam and levetiracetam tablets declared by xinlitai for production has been completed and entered into the stage of conclusion to be reviewed According to the new drug review process, xinlitai is expected to obtain production approval in the second half of this year Xinlitai is mainly engaged in the research and development and sales of cardiovascular drugs In the crisis of the main varieties losing the standard base drug market, the company's subsequent reserve varieties echelon has become a major concern of the market In addition to xinlitai, zuoxiracetam declared by Beijing New Pharmaceutical Co., Ltd and Chongqing shenghuaxi Pharmaceutical Co., Ltd will also undergo on-site inspection this month, but only the API, not the preparation  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.